Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Anti-TNF-α also helps with anaemia in IBD patients

09 Jan 2020
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Using anti-tumour necrosis factor-α (TNF-α) agents to treat inflammatory bowel diseases (IBD) also improves haemoglobin levels and may help resolve anaemia, a recent study has shown.

Researchers analysed the data of 362 IBD patients (mean age at recruitment, 35.1 years; 61 percent male) who were treated with anti-TNF-α drugs. Study outcomes were the treatment effects on disease activity, anaemia prevalence and blood markers after 6 and 12 months of medication.

Prior to initiating anti-TNF-α treatment, the mean haemoglobin concentration in the overall cohort was 13.2±1.9 g/dL; this was slightly higher in those with Crohn’s disease (CD) than in their ulcerative colitis (UC) counterparts. After 6 months of treatment, haemoglobin levels jumped to 14±1.7 in the overall cohort, with equivalent increases in the CD and UC subgroups. All changes were statistically significant when compared to baseline (p<0.001).

This increase continued until after 12 months of treatment, though changes relative to month 6 failed to achieve statistical significance.

Anti-TNF-α likewise had significant benefits on anaemia prevalence. At baseline, 29.3 percent (n=106) of all patients had anaemia (35.2 percent in UC patients and 27.3 percent in CD patients; p=0.154). This dropped to 14.4 percent (n=49) after 6 months of treatment (16.3 percent and 13.8 percent in the respective subgroups). By month 12, only 25 patients (7.8 percent) were anaemic.

The medication also resulted in drops in disease activity, as measured by serum levels of C-reactive protein (2.01±3.9 mg/dL at baseline to 0.81±2.2 mg/dL after 6 months, and to 0.44±0.7 mg/dL after 12 months; p<0.001 for both comparisons).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.